Proprietary 4% and 5% formulations achieved, paving the way for trials in microcystic lymphatic and venous malformations in 2026
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved—4% for its proprietary topical lotion and 5% for its dermal patch system.
With clinical trial and stability batch manufacturing set to begin in Q4 2025, Quoin plans to advance into clinical testing during the first half of 2026 across multiple indications, including microcystic lymphatic malformations and venous malformations. Currently, there are no FDA-approved treatments for these conditions.
Dr. Michael Myers, Chief Executive Officer, stated, “This is an important milestone for our topical rapamycin programs. We believe achieving 4% and 5% loadings in these proprietary systems could provide a competitive advantage by optimizing delivery at target sites. We’re moving forward into formal clinical development across several identified indications that complement our ongoing late-stage programs in Netherton Syndrome and Peeling Skin Syndrome.”
This milestone underscores Quoin’s commitment to expanding its rare disease portfolio, advancing new topical delivery technologies, and addressing critical unmet medical needs across dermatologic and vascular indications.
The post Quoin Pharmaceuticals Advances Topical Rapamycin Platform with Competitive Drug Loadings and New Clinical Indications appeared first on PRISM MarketView.
